{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:27:56Z","timestamp":1788964076534,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,4,24]],"date-time":"2007-04-24T00:00:00Z","timestamp":1177372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of the study was to assess the frequency of the concurrent use of gastric acid\u2010reducing agents among HIV\u20101\u2010infected patients treated with highly active antiretroviral therapy (HAART) combinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An anonymous, semistructured, self\u2010administered questionnaire was consecutively distributed among HIV\u20101\u2010infected patients at routine visits to specialized HIV clinics. The questionnaire contained 17 items asking specifically for information on current antiretroviral treatments and the use of gastric acid\u2010reducing agents as well as demographic data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 424 patients in 12 centres participated in the study: 85% were male, 88% were of German nationality, 82% were &gt;35 years of age and 201 (47.4%) were receiving a protease inhibitor (PI)\u2010containing HAART regimen. Of these, 74 (37%) had received an acid\u2010reducing drug within the previous 6 months and 43 (58%) were currently still on it. Two\u2010thirds of patients (64.9%) were treated with proton\u2010pump inhibitors (pantoprazole, omeprazole or esomeprazole) and 56% of patients on PI\u2010containing regimens had been taking these drugs for longer than 2 months and up to a maximum of 3 years. The majority of patients (77%) had received the prescription for the acid\u2010reducing drugs from their HIV specialist and the remaining patients had received over the counter (OTC) medication or prescriptions from other medical personnel.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A substantial subset of patients treated with HAART combinations, including those on PI\u2010containing regimens, were using concomitant acid\u2010reducing drugs, most often proton\u2010pump inhibitors. As negative drug\u2013drug interactions between some of the (boosted) PIs and gastric acid\u2010reducing agents have recently been reported, HIV physicians should take this into account when prescribing PI\u2010containing HAART combinations in order to avoid an additional risk of treatment failure.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2007.00456.x","type":"journal-article","created":{"date-parts":[[2007,4,24]],"date-time":"2007-04-24T17:21:01Z","timestamp":1177435261000},"page":"220-225","source":"Crossref","is-referenced-by-count":26,"title":["Concomitant use of gastric acid\u2010reducing agents is frequent among HIV\u20101\u2010infected patients receiving protease inhibitor\u2010based highly active antiretroviral therapy<sup>*<\/sup>"],"prefix":"10.1111","volume":"8","author":[{"given":"J","family":"Van Lunzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Liess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Arast\u00e9h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Walli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Daut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Sch\u00fcrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,4,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000197071.77482.6e"},{"key":"e_1_2_6_4_2","first-page":"794","article-title":"The importance of potency and durability in HIV patient antiretroviral therapy preferences","volume":"19","author":"Sherer RD","year":"2005","journal-title":"a telephone survey"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.9.708.31544"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.2.205"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00011"},{"key":"e_1_2_6_8_2","first-page":"563","article-title":"Beyond efficacy","volume":"19","author":"Sax PE","year":"2005","journal-title":"the impact of combination antiretroviral therapy on quality of life"},{"key":"e_1_2_6_9_2","unstructured":"Van HeeswijkRPG SaboJP CooperCet al. The pharmacokinetic interactions between tipranavir\/ritonavir 500\/200 mg bid and atorvastatin antacid and CYP3A4 in healthy adult volunteeers.5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome Italy April 2004 [Abstract 35]."},{"key":"e_1_2_6_10_2","unstructured":"AgarwalaS GrayK WangY GraselaD.Pharmacokinetic effect of omeprazole on atazanavir co\u2010administered with ritonavir in healthy subjects.12th Conference on Retroviruses and Opportunistic Infections Boston MA February 2005 [Abstract 658]."},{"key":"e_1_2_6_11_2","unstructured":"EMEA Public Statement. Important New Pharmacokinetic Data Demonstrating that REYATAZ (atazanavir sulfate) Combined with NORVIR (ritonavir) and Omeprazole should not be Co\u2010administered. EMEA\/202649\/2004 0.1.http:\/\/www.emea.eu.int.\/pdfs\/human\/press\/pus\/20264904en.pdf 2004."},{"key":"e_1_2_6_12_2","unstructured":"LuberA GargV GharakhanianS Vertex HIV Program Team. Survey of medication used by HIV\u2010infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART.7th International Congress on Drug Therapy in HIV Infection. Glasgow UK November 2004 [Abstract 206]."},{"key":"e_1_2_6_13_2","unstructured":"GuessantS Le CamusC LangJM.Survey on the gastric acid\u2010modifying medications use in HIV\u2010infectd (HIV+) patients on antiretroviral (ARV) treatment in France.10th EACS Conference. Dublin Ireland November 2005 [Abstract PE4.6\/1]."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000167477.20428.ce"},{"key":"e_1_2_6_15_2","first-page":"698","article-title":"Use of acid\u2010reducing agents in protease inhibitor\u2010based HAART and the potential for negative treatment outcomes","volume":"15","author":"Luber AD.","year":"2005","journal-title":"AIDS Read"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000189565.87600.4d"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000197075.56397.a5"},{"key":"e_1_2_6_18_2","first-page":"394","article-title":"Response to","volume":"41","author":"Khanlou H","year":"2006","journal-title":"Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir"},{"key":"e_1_2_6_19_2","first-page":"394","article-title":"Proton pump inhibitor therapy in atazanavir\u2010treated patients","volume":"41","author":"Furtek KJ","year":"2006","journal-title":"contraindicated?"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.3.341"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.4.511"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000226954.95094.39"},{"key":"e_1_2_6_23_2","unstructured":"Robert Koch Institut.Epidemiologisches Bulletin:Sonderausgabe A. Robert Koch Institute Berlin 2006: 1\u201316 (in German)."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2007.00456.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2007.00456.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T02:13:35Z","timestamp":1696904015000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2007.00456.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,24]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1111\/j.1468-1293.2007.00456.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2007.00456.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,24]]}}}